Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 20
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Elisa Uliassi, María Laura Bolognesi, Andrea Milelli
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 654-672
Closed Access | Times Cited: 2
Navigating the ERK1/2 MAPK Cascade
Ana Martín-Vega, Melanie H. Cobb
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1555-1555
Open Access | Times Cited: 35
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
Alexander Chan, Rebecca M. Haley, Mohd Altaf Najar, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future Scenario
Marianna Puzzo, Marzia De Santo, Catia Morelli, et al.
Small Science (2024) Vol. 4, Iss. 8
Open Access | Times Cited: 9
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Yufeng Xiao, Yaxia Yuan, Yi Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Inhibitors to degraders: Changing paradigm in drug discovery
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 7
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Emerging paradigms and recent progress in targeting ErbB in cancers
Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 552-576
Open Access | Times Cited: 5
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 5
Discovery of novel benzosultam CRBN ligands
Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, et al.
Bulletin of the Korean Chemical Society (2025)
Closed Access
Macrocyclic Peptide-Based Dual-Sensor Platform for Linkage-Specific Visualization of Ubiquitin Chain Assembling in Live Cells
Han Gao, Zhirong He, Jian Chen, et al.
Analytical Chemistry (2025)
Closed Access
Lysosome-Targeting Chimera Using Mannose-6-Phosphate Glycans Derived from Glyco-Engineered Yeast
Seobin Kim, Jiyeon Kang, D.R. An, et al.
Bioconjugate Chemistry (2025)
Closed Access
o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis
Haotian Xu, Qingyun Zhao, Dunyu Cai, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Cancer Specific CAIX‐Targeting Supramolecular Lysosome‐Targeting Chimeras (Supra‐LYTAC) for Targeted Protein Degradation
Do‐Hyun Kim, Gyeongseok Yang, Chaelyeong Lim, et al.
Advanced Science (2025)
Open Access
Advancing target validation with PROTAC technology
Margaret Spitz, Aseel Kashkush, Raphael I. Benhamou
Expert Opinion on Drug Discovery (2025)
Closed Access
Utilizing aptamers in targeted protein degradation strategies for disease therapy
Li Lin, Songbo Xie, Jun Zhou, et al.
The Journal of Pathology (2025)
Closed Access
Late‐Stage C−H Activation of Drug (Derivative) Molecules with Pd(ll) Catalysis
Su Yong Shim
Chemistry - A European Journal (2023) Vol. 29, Iss. 71
Open Access | Times Cited: 9
TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Dhanusha A. Nalawansha, Kyle Mangano, Willem den Besten, et al.
ChemBioChem (2023) Vol. 25, Iss. 4
Closed Access | Times Cited: 9
Differential analysis of Cereblon neosubstrates in rabbit embryos using targeted proteomics
Joel D. Federspiel, Natasha R. Catlin, William S Nowland, et al.
Molecular & Cellular Proteomics (2024) Vol. 23, Iss. 7, pp. 100797-100797
Open Access | Times Cited: 3
Ubiquitin recruiting chimera: more than just a PROTAC
Tatyana A. Grigoreva, Daria Novikova, Gerry Melino, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design
Harish Kumar, M. Elizabeth Sobhia
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1306-1318
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top